Menu Back to Real-World-Evidence-Conference

Overview

In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is increasingly becoming important for regulatory and reimbursement decision-making. RWE, in relation to the real-world data that is collected in combination with the advancement of artificial intelligence-based analytics platforms, has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions. Historically used for post-market safety monitoring, RWE is now becoming integrated throughout the product development lifecycle. DIA’s Real-World Evidence Conference will explore new and innovative applications of RWE and deliver cutting-edge insights through successful use cases, case examples, and practical applications on how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.



Who should attend?

Professionals involved in:

  • Real-World Evidence
  • Real-World Data
  • Epidemiology
  • Policy
  • Regulatory Science
  • Technology development
  • Data analytics
  • Clinical Research

Learning objectives

At the conclusion of this activity, participants should be able to:

  • Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
  • Discuss “lessons learned” from current uses of RWE by regulators, and how they can be applied for other future applications of RWE
  • Recognize general considerations and key features of successful RWE studies acceptable to the regulators for effective decision-making
  • Identify guidance and best practices for generating fit-for-purpose RWE for payers and HTA bodies
  • Define the expanding applications of RWE to support clinical trials and evidence generation
  • Evaluate the future applications of RWE in drug development
  • Appraise how mobile technologies, artificial intelligence, machine learning, and other technologies are being used to generate RWE
  • Evaluate how patient reported outcomes, electronic health records, and other patient data is expanding the resources for RWE

Program Committee

  • Brian  Bradbury, PhD, MA
    Brian Bradbury, PhD, MA Vice President, Center for Observational Research
    Amgen, United States
  • Dorothee  Bartels, PhD, MSc
    Dorothee Bartels, PhD, MSc Head of Global Real World Evidence and Digital Science
    UCB, Germany
  • Paul M. Coplan, DrSc, MBA, MSc, FISPE
    Paul M. Coplan, DrSc, MBA, MSc, FISPE Vice President, Medical Device Epidemiology & Real-World Data Analytics
    Johnson & Johnson, United States
  • Simon  Dagenais, PhD, MSc
    Simon Dagenais, PhD, MSc Senior Director, Real-World Evidence
    Pfizer Inc., United States
  • Marni  Hall, PhD, MPH
    Marni Hall, PhD, MPH Vice President, Clinical Evidence
    IQVIA, United States
  • James  Harnett, PharmD, MS
    James Harnett, PharmD, MS Executive Director, Health Economics & Outcomes Research
    Regeneron Pharmaceuticals, Inc., United States
  • Jingyu (Julia)  Luan, PhD
    Jingyu (Julia) Luan, PhD Global Regulatory Affairs Director, BioPharmaceuticals R&D, CVRM
    AstraZeneca, United States
  • David  Martin, MD, MPH
    David Martin, MD, MPH Vice President, Pharmacovigilance
    Moderna, United States
  • Delphine  Saragoussi, MD
    Delphine Saragoussi, MD Executive Director, Real-World Evidence
    Evidera, France
  • Mark  Stewart, PhD
    Mark Stewart, PhD Vice President, Science Policy
    Friends of Cancer Research, United States
  • Sulabha  Ramchandran, PhD
    Sulabha Ramchandran, PhD Vice President, Real world Data Strategy, Methods and Analytics
    GlaxoSmithKline, United States
  • Yun  Lu, PhD, MS
    Yun Lu, PhD, MS Mathematical Statistician, Office of Biostatistics and Epidemiology, CBER
    FDA, United States
Load More